We announce a unique data access agreement with leading Japanese medical data company
The agreement opens access to the world's second largest pharmaceutical market. Prospection can now provide global pharmaceutical companies and researchers access to comprehensive and longitudinal data covering more than 40 million people in
Combining our expertise in predictive analytics and machine learning with real-world healthcare data. Prospection's agreement with MDV will provide pharmaceutical companies across the world with unique access to patient diagnostic and medication data from hospitals across
Accessing patient history and prefecture level data, allows analysis of disease progression, disease outcomes and the mapping of disease courses to provide evidence on areas where there is opportunity to address unmet needs. When distilled further, this creates an opportunity to assess patient data on a regional level to find geographical areas where patients or health centres require additional support for specific disease and conditions. Leveraging these insights, companies can build programs to deploy their resources when and where they will have the greatest impact.
Prospection's access to
Global Healthcare Benefits
According to academic research,* only 60% of healthcare is in line with evidence-based guidelines, with the remaining 40% being classed as wasteful, low value or in some cases harmful. Through the analysis of the longitudinal history of hundreds of millions of patients, Prospection's technology can help the healthcare industry to assess the use, value and outcomes of treatments to find that 40% and identify how it can be optimised.
By enabling pharmaceutical companies and health researchers across the globe to better understand the full cycle of health conditions and disease journeys, this data will allow global life science companies to:
1. Collect patient and market insights
Through the analysis of specific health conditions and patient journeys, pharmaceutical companies can determine where, when and how to invest their resources and how to position their brand within the Japanese pharmaceutical market while forecasting supply chain, and developing models for market access.
2. Find patients and develop tactical plans
Life science companies can utilise the data to identify where patients with the highest disease burden for their treatment offerings are being treated geographically. Companies can then deploy their regional in-field teams with the right messages to support clinicians to help these patients requiring treatment. .
3. Publish data
Access to one of the most comprehensive Japanese medical data sets also creates an opportunity to add to the clinical body of evidence for health conditions to help inform a better understanding of specific diseases.
4. Receive decision support
Provide trigger events to assist with targeted education when it is needed most, supporting clinician at point of care with the patient.
What does this opportunity mean for
When considering how this agreement brings Prospection one step closer to our mission to make a different to patient outcomes through analysing health data. CEO and Co-founder,
'We are very excited to be working with MDV in our latest data access agreement. Combining MDV's large and comprehensive dataset with Prospections global reach and extensive expertise working with datasets across the world will not only allow MNC pharmaceutical companies to work with patient data from
Contact:
General
Global Head Office
Level 6 Sydney Central
477 Pitt Street Haymarket
NSW 2000
T: +61 2 9209 4035
T: +1 844 719 0696
E: prospection@prospection.com
Investors
E: investors@prospection.com
(C) 2022 Electronic News Publishing, source